Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Hydrolyzed by plasma esterases.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Renal excretion of parent drug and metabolites: <5% unchanged.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Minimal; <5% bound to plasma proteins.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No dose adjustment required; negligible systemic absorption.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No dose adjustment required; negligible systemic absorption.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Not available.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to any component of the formulation.
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
None known.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.